Skip to main content
SpringerLink
Log in

Flow Cytometric Evaluation of Multidrug Resistance Proteins

  • Protocol
  • First Online:
Multi-Drug Resistance in Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 596))

Abstract

There are several ways to detect proteins on cells. One quite frequently used method is flow cytometry. This method needs fluorescently labeled antibodies that can attach selectively to the protein to be investigated for flow cytometric detection. Flow cytometry scans individual cells, virtually without their surrounding liquid, and can scan many cells in a very short time. Because of this advantage of flow cytometry, it was adapted to investigate transport proteins on normal and cancerous human cells and cell lines. These transport proteins play important roles in human metabolism. Absorption in the intestine, excretion at the kidney, protection of the CNS compartment and the fetus from xenobiotics, and other vital functions depend on these transporters. However, several transporters are overexpressed in cancer cells. These overexpressed transporters pump out anticancer drugs from the cells and prevent their curative effects. The detection and quantitation of these types of transporters in cancer cells is important for this reason. Here, we review literature on flow cytometric detection of the three most studied transporters: P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance protein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29

    Article  CAS  PubMed  Google Scholar 

  2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234

    Article  CAS  PubMed  Google Scholar 

  3. Aleman C, Annereau JP, Liang XJ et al (2003) P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63:3084–3091

    CAS  PubMed  Google Scholar 

  4. Broxterman HJ, Lankelma J, Pinedo HM et al (1997) Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 11:1110–1118

    Article  CAS  PubMed  Google Scholar 

  5. Broxterman HJ, Lankelma J, Pinedo HM (1996) How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 32A:1024–1033

    Article  CAS  PubMed  Google Scholar 

  6. Pallis M, Das-Gupta E (2005) Flow cytometric measurement of functional and phenotypic P-glycoprotein. Methods Mol Med 111:167–181

    CAS  PubMed  Google Scholar 

  7. Leith CP, Kopecky KJ, Chen IM et al (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086–1099

    CAS  PubMed  Google Scholar 

  8. Krishan A (2000) Monitoring of cellular resistance to cancer chemotherapy: drug retention and efflux. In: Darzynkiewicz Z, Crissman HA, Robinson JP (eds) Cytometry, part B, 3rd edn. Academic, San Diego, CA, pp 193–209

    Google Scholar 

  9. Krishan A (2002) Flow cytometric monitoring of drug resistance in human tumor cells. Methods Cell Sci 24:55–60

    Article  CAS  PubMed  Google Scholar 

  10. Ford J, Hoggard PG, Owen A, Khoo SH, Back DJ (2003) A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods 274:129–137

    Article  CAS  PubMed  Google Scholar 

  11. Feller N, Kuiper CM, Lankelma J et al (1995) Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72:543–549

    CAS  PubMed  Google Scholar 

  12. Aszalos A, Weaver JL (1998) Estimation of drug resistance by flow cytometry. In: Jaroszeski MJ, Heller R (eds) Flow cytometry protocols. Humana, Totowa, NJ, pp 117–122

    Google Scholar 

  13. Beck WT, Grogan TM, Willman CL et al (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res 56:3010–3020

    CAS  PubMed  Google Scholar 

  14. Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28:522–528

    CAS  PubMed  Google Scholar 

  15. Janneh O, Jones E, Chandler B, Owen A, Khoo SH (2007) Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 60:987–993

    Article  CAS  PubMed  Google Scholar 

  16. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ (2001) Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 17:1329–1332

    Article  CAS  PubMed  Google Scholar 

  17. Braga F, Ayres-Saraiva D, Gattass CR, Capella MA (2007) Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy. Cancer Lett 248:147–152

    Article  CAS  PubMed  Google Scholar 

  18. Echevarria-Lima J, Kyle-Cezar F, DF PL, Capella L, Capella MA, Rumjanek VM (2005) Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line. Immunology 114:468–475

    Article  CAS  PubMed  Google Scholar 

  19. McAleer MA, Breen MA, White NL, Matthews N (1999) pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274:23541–23548

    Article  CAS  PubMed  Google Scholar 

  20. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172–176

    Article  CAS  PubMed  Google Scholar 

  21. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798–1804

    CAS  PubMed  Google Scholar 

  22. Belinsky MG, Guo P, Lee K et al (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67:262–268

    Article  CAS  PubMed  Google Scholar 

  23. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

    Article  PubMed  Google Scholar 

  24. Minderman H, Suvannasankha A, O’Loughlin KL et al (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59–65

    Article  CAS  PubMed  Google Scholar 

  25. Kawabata S, Oka M, Soda H et al (2003) Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 9:3052–3057

    CAS  PubMed  Google Scholar 

  26. Ee PL, He X, Ross DD, Beck WT (2004) Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 3:1577–1583

    CAS  PubMed  Google Scholar 

  27. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47–50

    CAS  PubMed  Google Scholar 

  28. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512

    Article  CAS  PubMed  Google Scholar 

  29. Zamber CP, Lamba JK, Yasuda K et al (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19–28

    Article  CAS  PubMed  Google Scholar 

  30. Vethanayagam RR, Wang H, Gupta A et al (2005) Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33:697–705

    Article  CAS  PubMed  Google Scholar 

  31. Doyle LA, Yang W, Gao Y, Ordonez JV, Ross DD (1996) Novobiocin increases the accumulation of daunorubicin in an atypical multidrug-resistant breast cancer subline. Proc Am Soc Clin Oncol 15:398

    Google Scholar 

  32. Hausner P, Venzon DJ, Grogan L, Kirsch IR (1999) The “comparative growth assay”: examining the interplay of anti-cancer agents with cells carrying single gene alterations. Neoplasia 1:356–367

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. We would like to thank Dr. Michael Gottesman for his hospitality and encouragement and George Leiman for editorial assistance.

Author information

Authors and Affiliations

  1. Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Adorjan Aszalos

  2. Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Barbara J. Taylor

Authors
  1. Adorjan Aszalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara J. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adorjan Aszalos .

Editor information

Editors and Affiliations

  1. College of Life Sciences, Nankai University, Weijin Rd. 94, Tianjin, 300071, China, People's Republic

    Jun Zhou

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Aszalos, A., Taylor, B.J. (2010). Flow Cytometric Evaluation of Multidrug Resistance Proteins. In: Zhou, J. (eds) Multi-Drug Resistance in Cancer. Methods in Molecular Biology, vol 596. Humana Press. https://doi.org/10.1007/978-1-60761-416-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-416-6_7

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-415-9

  • Online ISBN: 978-1-60761-416-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation